Abstract
Objectives Currently used prognostic tools for patients with SARS-CoV-2 infection are based on clinical and laboratory parameters measured at a single point in time, usually on admission. We aimed to determine how dynamic changes in clinical and laboratory parameters relate to SARS-CoV-2 prognosis.
Design retrospective, observational cohort study using routinely collected clinical data to model the dynamic change in prognosis of SARS-CoV-2.
Setting a single, large hospital in England.
Participants all patients with confirmed SARS-CoV-2 admitted to Nottingham University Hospitals (NUH) NHS Trust, UK from 1st February 2020 until 30th November 2020.
Main outcome measures Intensive Care Unit (ICU) admission, death and discharge from hospital.
Statistical Methods We split patients into 1st (admissions until 30th June) and 2nd (admissions thereafter) waves. We incorporated all clinical observations, blood tests and other covariates from electronic patient records and follow up until death or 30 days from the point of hospital discharge. We modelled daily risk of admission to ICU or death with a time varying Cox proportional hazards model.
Results 2,964 patients with confirmed SARS-CoV-2 were included. Of 1,374 admitted during the 1st wave, 593 were eligible for ICU escalation, and 466 had near complete ascertainment of all covariates at admission. Our validation sample included 1,590 confirmed cases, of whom 958 were eligible for ICU admission. Our model had good discrimination of daily need for ICU admission or death (C statistic = 0.87 (IQR 0.85-0.90)) and predicted this daily prognosis better than previously published scores (NEWS2, ISCARIC 4C). In validation in the 2nd wave the score overestimated escalation (calibration slope 0.55), whilst retaining a linear relationship and good discrimination (C statistic = 0.88 (95% CI 0.81 −0.95)).
Conclusions A bespoke SARS-CoV-2 escalation risk prediction score can predict need for clinical escalation better than a generic early warning score or a single estimation of risk at admission.
What is already known on this topic SARS-CoV-2 is a recently emerged viral infection, which presents typically with flu like symptoms, can have severe sequelae and has caused a pandemic during 2020.
A number of risk factors for poor outcomes including obesity, age and comorbidity have been recognized.
Risk scores have been developed to stratify risk of poor outcome for patients with SARS-CoV-2 at admission, but these do not take account of dynamic changes in severity of disease on a daily basis.
What this study adds We have developed a dynamic risk score to predict escalation to ICU or death within the next 24 hours.
Our score has good discrimination between those who will and not require ICU admission (or die) in both our derivation and validation cohorts.
Our bespoke SARS-CoV-2 escalation risk prediction score can predict need for clinical escalation better than a generic early warning score or a single estimation of risk at admission.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04473105
Funding Statement
This work was funded by Nottingham University Hospitals NHS Trust and the University of Nottingham. Nottingham University Hospitals NHS Trust also sponsored the study. Neither organisation beyond their employees who are the authors had any role in the design, analysis, interpretation, writing up or submission of this work. All data was collected originally during routine clinical care in Nottingham University Hospitals NHS Trust.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval for this work was granted via an Nottingham University Hospitals NHS Trust Clinical Effectiveness Team audit (reference: 20-153C), the NUH Caldicott Guardian, Data Protection Impact Assessment (reference: 436) and as a research study (ethics approval) via the NHS Health Research Authority (HRA) Integrated Research Application System (IRAS) (reference: 282490). The HRA confirmed that individual patient consent was not required for this work.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Guarantor Colin Crooks
Contributorship All authors contributed, in part, to the planning, conduct, and reporting of the work described in the article and all authors approved the final submitted draft. Colin Crooks is the guarantor. The guarantor accepts full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.
Copyright The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.
No competing interests All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
Data Availability
The individual data used in this study, under the information governance and HRA IRAS approvals, are unable to be shared beyond NUH Hospitals NHS Trust.
